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Abstract
Background: There is a need for new vaccines for tuberculosis (TB) that protect against adult pulmonary disease in regions
where BCG is not effective. However, BCG could remain integral to TB control programmes because neonatal BCG protects
against disseminated forms of childhood TB and many new vaccines rely on BCG to prime immunity or are recombinant
strains of BCG. Interferon-gamma (IFN-c) is required for immunity to mycobacteria and used as a marker of immunity when
new vaccines are tested. Although BCG is widely given to neonates IFN-c responses to BCG in this age group are poorly
described. Characterisation of IFN-c responses to BCG is required for interpretation of vaccine immunogenicity study data
where BCG is part of the vaccination strategy.
Methodology/Principal Findings: 236 healthy Gambian babies were vaccinated with M. bovis BCG at birth. IFN-c,
interleukin (IL)-5 and IL-13 responses to purified protein derivative (PPD), killed Mycobacterium tuberculosis (KMTB), M.
tuberculosis short term culture filtrate (STCF) and M. bovis BCG antigen 85 complex (Ag85) were measured in a whole blood
assay two months after vaccination. Cytokine responses varied up to 10 log-fold within this population. The majority of
infants (89–98% depending on the antigen) made IFN-c responses and there was significant correlation between IFN-c
responses to the different mycobacterial antigens (Spearman’s coefficient ranged from 0.340 to 0.675, p=10
26–10
222). IL-
13 and IL-5 responses were generally low and there were more non-responders (33–75%) for these cytokines. Nonetheless,
significant correlations were observed for IL-13 and IL-5 responses to different mycobacterial antigens
Conclusions/Significance: Cytokine responses to mycobacterial antigens in BCG-vaccinated infants are heterogeneous and
there is significant inter-individual variation. Further studies in large populations of infants are required to identify the
factors that determine variation in IFN-c responses.
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Introduction
Tuberculosis (TB) is responsible for the deaths of over 2 million
people annually [1], and efforts to control disease are failing in
many high burden countries. Two main strategies underpin TB
control: prevention of disease through vaccination and prevention
of transmission through rapid diagnosis and treatment of infectious
smear-positive pulmonary cases. Mycobacterium bovis bacillus Calm-
ette-Guerin (BCG) is currently the only available vaccine against
TB. It is widely given to infants as part of the WHO Expanded
Programme on Immunization (EPI) in countries where TB is
endemic. There is good evidence that BCG protects against
disseminated forms of TB in childhood, including TB meningitis
and miliary TB [2,3]. However, the ability of BCG to prevent
pulmonary TB in adults, who bear the brunt of the global burden,
varies considerably and protection is lowest in countries where TB
is most prevalent [4]. The Global Plan to Stop TB 2006–2015 has
therefore identified research and development for new vaccines as
a critical component of its strategy to eradicate TB [5].
A number of new TB vaccines are at various stages of
development (reviewed by Fletcher and McShane [6]). Given
the protection afforded to young children, there are strong
logistical and ethical arguments to continue to use BCG in EPI
vaccination programmes. Of particular interest are recombinant
BCG vaccines which aim to enhance the immunogenicity of
current BCG strains through the reintroduction of genes that were
deleted during the attenuation of a virulent M. bovis strain [7].
Examples include the genes encoding the 30-kDa major secretory
protein and ESAT-6 within the RD1 region of M. bovis [8,9].
Alternatively, current BCG vaccines can be used to prime immune
responses that are subsequently boosted with new subunit vaccines
derived from immunodominant M. tuberculosis antigens such as
antigen 85 [10,11]. Regardless of which approach eventually
proves to give the best protection for TB, robust tools for
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3485evaluating their ability to induce protective immunity are also
required.
Studies in both animals and humans have demonstrated that
interferon-c (IFN-c) is critical(though notsufficient) forimmunityto
M. tuberculosis [12,13,14]. For this reason, IFN-c responses to
relevant antigens are widely used as the best available correlates of
protective immunity in the evaluation of new vaccines for TB [15].
IFN-c responses also underpin new diagnostic testsfor TB including
the QuantiFERON Gold (Cellestis, Victoria, Australia) and T-
SPOT.TB (Immunotec, Oxford, UK) assays [16] which are widely
applied for the detection of latent infection. Thus, an understanding
ofthe determinantsofvariationinIFN-c responsestomycobacterial
antigens is critical for the accurate interpretation of data derived
from trials of both new vaccines and diagnostic tools.
It is recognised that multiple factors influence IFN-c responses
to mycobacterial infection. These include host nutritional status
[17], unspecified host genetic factors [18,19], exposure to other
mycobacteria [20] and for BCG specifically, the strain and the
route of immunization which can lead to variation in the immune
response in infants [21]. Despite the fact that BCG has been
administered since 1927, it is only recently that IFN-c responses to
BCG have been characterised in this age group. Furthermore,
although it is now recognised that newborn human infants are able
to generate T helper lymphocyte type 1 (Th1) responses to
neonatal BCG [22,23], the relationship between IFN-c and the
type 2 cytokines IL-13 and IL-5 have not been explored in this age
group. We therefore sought to characterise the variation in IFN-c,
IL-13 and IL-5 responses to BCG in a large cohort of healthy
Gambian infants who were vaccinated with BCG at birth.
Methods
Study population
The study was conducted at the Medical Research Laborato-
ries, The Gambia, with approval from The Gambia Government/
Medical Research Council (MRC) Ethics Committee.
With the mother’s informed consent, newborn infants were
enrolled within 24 hours of birth at the Royal Victoria Teaching
Hospital (the referral hospital in the capital Banjul) or at one of
two health centres (Serrekunda and Fajikunda) in the same district.
Consent was given verbally due to the high level of illiteracy within
the population – this was approved by The Gambia Government/
Medical Research Council (MRC) Ethics Committee. Twins and
neonates born to mothers with systemic infection at the time of
delivery, or with a history suggestive of contact with TB and those
with congenital defects or with birth weight less than 2.5 kg were
excluded from the study. All subjects were vaccinated at enrolment
(i.e. within 24 hours of birth) with 0.05 ml of BCG (Aventis
Pasteur, Lyon, France) intradermally in the left deltoid region.
Other vaccines were given as per the EPI programme.
Whole blood assay and antigens
BCG immunogenicity was evaluated 2 months after vaccination
using a whole blood assay, due to the limited amount of blood
available [24]. One to two ml of heparinized blood was diluted in
9 volumes of RPMI 1640 medium (BioWittaker, Verviers,
Belgium) supplemented with 100 U/ml penicillin and 100 mg/
ml streptomycin (LifeTechnologies, Paisley, Scotland). Diluted
blood was incubated for 2 or 6 days in 96-well plates (200 ml/well)
(Becton Dickinson, Rutherford, NJ) containing antigen prepara-
tions in duplicates [25]. Mycobacterial antigens included M.
tuberculosis purified protein derivative (PPD, RT49, 10 mg/ml;
Statens Serum Institut, Denmark), M. tuberculosis short term culture
filtrate (STCF, 10 mg/ml; a gift from Dr Peter Andersen, Statens
Serum Institut, Denmark), killed M. tuberculosis (KMTB) and M.
bovis BCG Ag85 complex (both at 10 mg/ml, and given by Dr Kris
Huygen, Institut Pasteur du Brabant, Belgium). Wells containing
medium alone or phytohaemaglutinin (PHA-L, Sigma Chemicals)
were used as the negative and positive controls, respectively. We
chose mainly M. tuberculosis antigens (PPD, KMTB and STCF)
because we were primarily interested in immunity induced by
BCG in the context of protection against TB, and Ag85 was
chosen as it is a candidate subunit vaccine antigen.
Cytokine assays
Cytokine concentrations in supernatants collected on day 2
(PHA) or day 6 (medium and antigens) were measured by enzyme-
linked immunosorbent assay, using commercially available kits
(IFN-c and IL-5; BioSource Europe, Fleurus, Belgium; IL-13;
Diaclone, Besanc ¸on, France). The lower limit of detection was
10 pg/ml for IFN-c and 1.5 pg/ml for IL-5 and IL-13. These
values were used as the cut off to determine non-responders.
Background production of cytokines measured in control wells was
subtracted from that measured in Ag-stimulated wells and
duplicates for each antigen averaged.
Tuberculin skin testing
Tuberculin skin testing (TST) was performed after phlebotomy
on the volar surface of the forearm with 2TU of PPD (Statens
Serum Institute, Belgium) using the Mantoux method [26].
Candida albicans antigen (Evans Medical Limited, UK) was used
as the skin test control antigen. The length of the maximum
transverse induration at 48–72 hours was taken as the response.
The vertical and horizontal size of the BCG scar was also
measured and the mean recorded at the time of cytokine
assessment.
Data analysis
Logarithm transformation was applied to all cytokine data
before statistical analysis. All statistical analyses and graphics were
done using the R software package (http://www.r-project.org/).
The Kruskal-Wallis test was used to compare median levels of
IFN-c response to PPD for data grouped by TST response size.
Spearman’s rank correlation coefficient was used to measure
correlation between cytokine responses to mycobacterial antigens
and PHA, TST response and BCG scar size. Non-responders were
excluded from correlation analysis. We arbitrarily used cut-off of
r=0.3–0.5 as evidence of weak correlation and r$0.5 as evidence
of strong correlation.
Results
A total of 236 babies were studied of which 124 (53%) were
female. Only healthy babies who were normal on examination
without clinical evidence of congenital abnormalities or infection
were enrolled. The average birth weight was 3.189 (60.49) kg for
male infants and 3.185 (60.55) kg for female infants. A BCG scar
was present in 221 (94%) of the babies.
Cytokine responses
To evaluate cellular immune responses to neonatal BCG we
measured IFN-c, IL-13 and IL-5 responses to the mycobacterial
antigens PPD, Ag85, STCF and KMTB, and compared them to
PHA responses. IFN-c responses were measured in all 236 (100%)
infants. Due to limited volumes of supernatant collected in some
infants, IL-13 and IL-5 responses to the various mycobacterial
antigens could only be measured in 200 (85%) and 155 (66%)
babies respectively. The geometric means and 95% confidence
Infant Immune Responses to BCG
PLoS ONE | www.plosone.org 2 October 2008 | Volume 3 | Issue 10 | e3485intervals for the cytokine responses are presented in Table 1.
Histograms showing the distribution of IFN-c, IL13 and IL-5
responses to PHA, PPD, Ag85, STCF and KMTB are shown in
Figure 1. There was no correlation between birth weight and
magnitude of response for any of the responses we studied and
there were no differences between male and female responses
within the total population (data not presented).
The most striking observation is that our data show significant
inter-individual variation of up to 10 log-fold differences for all
three cytokine responses to both PHA and the mycobacterial
antigens tested. Two response patterns emerged that could be
differentiated by the numbers of non-responders, which were
notably higher for IL-13 and IL-5 responses to mycobacterial
antigens (Figure 1). For phenotypes where the majority of infants
responded, the data approximated to a normal distribution after
log transformation. IFN-c was induced in response to mycobac-
terial antigens in the majority of infants. Over 98% of infants
produced IFN-c in response to PPD and KMTB and 89% of
infants made IFN-c responses to Ag85 and STCF. These data are
consistent with our previous work which demonstrated that infants
generated predominantly Th1 responses to mycobacterial antigens
following neonatal BCG [22,27].
In contrast to the IFN-c responses, IL-13 and IL-5 responses
were generally low. There were also considerably more non-
responders in these groups (Table 1 and Figure 1). This is
consistent with previously published data and again reflects the
fact that BCG is a potent inducer of Th1 responses, even in young
infants [23,27]. As with IFN-c, a higher proportion of infants
responded to PPD and KMTB than to the secreted antigens STCF
and Ag85. Thus, 77% and 69% of infants made an IL-13 response
to PPD and KMTB respectively while only 56 and 31% responded
to STCF and Ag 85 respectively. This pattern was seen also in IL-
5 responses with 68% and 50% responding to PPD and KMTB
respectively, but only 40% and 25% responding to STCF and
Ag85 respectively. Within the group of responders, there was
again a 6 log-fold range in the magnitude of response that
approximated to a normal distribution when non-responders were
excluded. Responses to PPD and KMTB were generally higher for
all cytokines compared to STCF and Ag85, reflecting the fact that
PPD and KMTB contain many more antigens that will stimulate
more T cell clones.
PHA was included as a positive control for this study yet only
82%, 72% and 28% of infants produced IFN-c, IL13 or IL-5
respectively to this antigen. However, given that over 98% of
infants had IFN-c responses to PPD and the negative controls
were negative, the low PHA responses reflect a true biological
response rather than any technical problem with the assay used.
Cytokine correlations
Next, we examined the relationship between cytokine responses
to the various antigens tested. Non-responders were excluded from
the analysis to avoid non-responder correlations artificially
skewing the correlation coefficients. We firstly tested for
correlation between the magnitude of cytokine response to the
various antigens for each cytokine separately. Figures 2, 3 and 4
show scatter plots for each pairwise correlation for IFN-c, IL-13
and IL-5 respectively and the correlation results are summarised in
Table 2. We then considered correlation between the three
cytokines for each antigen separately (Table 3 and figure 5).
Intra-cytokine correlations: PHA responses. IFN-c
responses to PHA showed correlation with Ag85 IFN-c
responses (Spearman rank correlation coefficient r=0.466,
p=1.37610
210) but no correlation with IFN-c responses to the
other mycobacterial antigens PPD, KMTB and STCF (Figure 2).
Interleukin-13 production in response to PHA correlated with
IL-13 responses to PPD (r=0.381, p=1.2610
25), Ag 85
(r=0.379, p=0.0085) and STCF (r=0.402, p=7.66610
25)
(Figure 3). A weaker correlation was observed with IL-13
production in response to KMTB, though this did not reach
statistical significance.
Table 1. Cytokine responses to mycobacterial antigens in BCG vaccinated infants.
Cytokine Antigen
a Numbers available
b Non-responders (%)
c Geometric mean (pg/ml, 95% CI)
IFN-c PHA 232 42 (18) 58.37 (42.59–80.02)
N=236 PPD 236 5 (2) 845.39 (692.67–1031.79)
Ag85 228 26 (11) 76.23 (56.14–103.52)
STCF 236 27 (11) 99.15 (73.21–134.28)
KMTB 236 2 (1) 1574.70 (1278.33–1939.78)
IL-13 PHA 200 55 (28) 11.79 (8.99–15.47)
N=200 PPD 200 45 (23) 8.02 (6.46–9.95)
Ag85 200 138 (69) 1.61 (1.42–1.82)
STCF 200 87 (44) 3.64 (2.99–4.43)
KMTB 200 61 (31) 6.45 (5.20–8.01)
IL-5 PHA 153 110 (72) 1.97 (1.60–2.43)
N=155 PPD 154 64 (42) 7.83 (5.68–10.80)
Ag85 154 115 (75) 2.18 (1.72–2.78)
STCF 155 93 (60) 3.89 (2.90–5.21)
KMTB 153 76 (50) 5.57 (4.08–7.61)
aConcentration 10 mg/ml.
bDiscrepancies between number available and total number in study are due to technical failure for a few samples in the IFN-c and IL-5 groups.
cnon-responders defined as cytokine level of 0 or less after background subtracted; percentages rounded up to nearest integer.
IFN-c: interferon-gamma; IL-13: interleukin-13; IL-5: interleukin-5; PHA: phytohaemagglutinin; PPD: purified protein derivative; Ag85: antigen 85; STCF: short term culture
filtrate; KMTB: killed Mycobacterium tuberculosis.
doi:10.1371/journal.pone.0003485.t001
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IL-5 responses to any of the mycobacterial antigens tested,
although the numbers available to for analysis were too small in
this group to draw any meaningful conclusions (Figure 4).
Intra-cytokine correlations: mycobacterial antigen
responses. When responses to mycobacterial antigens were cons-
idered for each cytokine individually, we found strong correlation
between IFN-c responses to PPD and IFN-c responses to Ag85,
KMTBand STCF,all ofwhichhada Spearman’scoefficient of .0.5
(p,10
215–10
228)( F i g u r e2a n dT a b l e2 ) .I F N - c responses to STCF
and KMTB were also strongly correlated with r=0.615
(p=3.57610
223), whilst IFN-c induced by Ag85 correlated with
both STCF (r=0.503, p=2.39 610
213)a n dK M T B( r=0.340,
p=8.22610
27). In summary, all IFN-c responses to all
mycobacterial antigens correlated with each other. Some
correlations were stronger than others, with correlations between
PPD and the other mycobacterial antigens being the strongest.
Interleukin-13 responses (shown in figure 3) to PPD correlated
strongly with IL-13 responses to STCF and KMTB, but not to Ag
85. However, 69% of infants did not make IL-13 responses to Ag
85, which may also explain the lack of correlation between IL-13
responses to KMTB and Ag85. We did observe correlation
between IL-13 responses to STCF and Ag 85 (r=0.446,
p=3.6610
24) and IL-13 responses to KMTB and STCF
(r=0.417, p=1.18610
25).
Given the generally low response rates for IL-5 and the smaller
number of samples tested, it is perhaps not surprising that we did
not observe strong correlations for IL-5 compared to IFN-c and
IL-13 (figure 4). Even so, IL-5 responses to PPD were strongly
correlated with IL-5 responses to both STCF (r=0.565,
p=4.59610
26) and KMTB (r=0.635, p=7.72610
29),but not
Ag 85, and likewise there was strong correlation between IL-5
responses to STCF and KMTB (r=0.610, p=1.26610
26)
(Table 2).
Figure 1. Histograms showing distribution of cytokine responses to mycobacterial antigens and PHA in BCG vaccinated infants.
Table 1 indicates total numbers of infants included in each histogram plot. The asterisk denotes .120 babies did not make IL-13 responses to Ag85
(n=138). IFN-c: interferon-gamma; IL-13: interleukin-13; IL-5: interleukin-5; PHA: phytohaemagglutinin; PPD: purified protein derivative; Ag85: antigen
85; STCF: short term culture filtrate; KMTB: killed Mycobacterium tuberculosis.
doi:10.1371/journal.pone.0003485.g001
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for the different cytokines to individual antigens. The results are
presented in figure 5 and summarised in table 3. It should be noted
that for some combinations the numbers of individuals who had
made more than one cytokine response to a given antigen were
small, and results should be interpreted with caution. Thus, IL-13
and IL-5 responses to Ag85 were apparently strongly inversely
correlated (r=20.654 p=0.0211) but only 12 subjects (5%) were
included in the analysis. Otherwise, we did not observe any strong
correlation (i.e. r$0.5) between any of the cytokine responses to
Figure 2. Correlations between interferon-c responses to PHA and various mycobacterial antigens. N=number of infants who
responded to both antigens considered. Rho: Spearman’s rank correlation coefficient; IFN-c: interferon-gamma; PHA: phytohaemagglutinin; PPD:
purified protein derivative; Ag85: antigen 85; STCF: short term culture filtrate; KMTB: killed Mycobacterium tuberculosis.
doi:10.1371/journal.pone.0003485.g002
Figure 3. Correlations between interleukin-13 responses to PHA and various mycobacterial antigens. N=number of infants who
responded to both antigens considered. Rho: Spearman’s rank correlation coefficient; IL-13: interleukin-13; PHA: phytohaemagglutinin; PPD: purified
protein derivative; Ag85: antigen 85; STCF: short term culture filtrate; KMTB: killed Mycobacterium tuberculosis.
doi:10.1371/journal.pone.0003485.g003
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KMTB were weakly correlated and the same responses for PPD
and STCF were just below our arbitrary cut off for reporting weak
correlation at r=0.226, p=0.005 and r=0.285, p=0.003
respectively. Likewise, there was a weak correlation between IL-
13 and IL-5 responses to PHA (r=0.334) but this was not
statistically significant.
Cytokine responses, tuberculin skin tests and BCG scar
The average diameter of the BCG scar was recorded in the 236
babies in whom cytokine studies were performed (Figure 6A). The
mean BCG scar size was 5.19 (62.18) mm. There was no
correlation between cytokine response and size of BCG scar (data
not shown). Tuberculin skin tests (TST) were measured in 202
babies at 2 months of age - 34 (14.4%) of the 236 babies who
underwent skin testing at the time of blood sampling were not
available 48–72 hours later for skin test reading. The mean
response was 8.1165 mm. Forty-three babies (21.2%) did not
react to intradermal PPD and 98 (49%) babies had a response of
$10 mm (Figure 6B). There was no correlation between TST
diameter and magnitude of IFN-c response to PPD in the 202
babies for whom both data were available (r=0.238,
p=6.78610
24; Figure 6C). We also compared the median IFN-
c concentration between groups when infants were grouped
according to the conventional cut-offs for interpreting TST
responses: 0, ,5 mm, 6–10 mm, 11–15 mm and 16–20 mm
(Figure 6D). Again, we found no association between magnitude of
in vitro IFN-c and TST response (Figure 6D). All 43 babies who
did not respond to intradermal PPD responded to mycobacterial
antigens in vitro (Figure 6C).
Discussion
Although BCG has been administered to millions of infants
around the world, the immune responses induced by BCG in this
age group are poorly characterised compared to other vaccines.
Given the drive for new TB vaccine strategies that are likely to
include BCG, whether as a recombinant BCG strain or in its
current form with a boosting vaccine such as the MVA85, there is
a need to understand immunity to BCG in greater depth in order
to fully evaluate newer vaccines. Our previous work in The
Gambia has shown that responses to BCG given at birth were
predominantly T helper lymphocyte type 1 responses and of a
similar magnitude to responses induced in adults [22,27]. This has
subsequently been confirmed by other groups in other settings and
using different methodology [23,28]. These findings have now
been replicated in a much larger cohort presented in this paper
where we have demonstrated that the majority of infants (89–98%
of infants depending on the antigen) developed antigen specific
IFN-c response to mycobacterial antigens following BCG
vaccination. We have also reported data on IL-13 and IL-5
responses which have not been described in previous studies. We
found a large number of infants did generate IL-13 and IL-5
response to both PHA and mycobacterial antigens. Given the high
IFN-c response rate to PPD in the same infants, we are confident
that this does not reflect a technical problem with the assay. The
fact that there are more non-responders for IL-13 and IL-5 is to be
expected because we are studying a Th1 response and this has
been reported by us and others previously [22,23]. The higher
frequency of non-responders for some antigen/cytokine combina-
tions may also relate to the fact we used a whole blood assay –
using purified peripheral blood mononuclear cell assays would
have increased sensitivity by increasing the numbers of responsive
cells being stimulated, but was not practical for the scale of study
we wished to conduct when blood volumes were limited due to the
young age of the study participants. Widespread surveys of PHA
responses in this age group have not previously been reported.
Given our PHA data, we would suggest that PHA is not the best
positive control antigen for this age group and alternative antigens
such as Stapylococcus aureus Cowan should be investigated.
Figure 4. Correlations between interleukin-5 responses to PHA and various mycobacterial antigens. N=number of infants who
responded to both antigens considered. Rho: Spearman’s rank correlation coefficient; interleukin-5; PHA: phytohaemagglutinin; PPD: purified protein
derivative; Ag85: antigen 85; STCF: short term culture filtrate; KMTB: killed Mycobacterium tuberculosis.
doi:10.1371/journal.pone.0003485.g004
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sample and found that 78% of babies had a positive TST 2
months after BCG. This is similar to other Sub-Saharan African
populations [29]. Since exposure to non-tuberculous mycobacteria
is likely to be low in this population in the first 2 months of life (see
below for further discussion of this) this probably reflects recent
BCG vaccination. However, our previous work has shown that by
the age of 5 months, approximately 20% of unvaccinated infants
have developed a positive TST indicating that exposure to NTM
may also contribute [30]. Further longitudinal studies of TST
responses following BCG in TB-endemic regions are warranted. In
this work we have expanded our previous studies in The Gambia
and demonstrated that there was no correlation between TST
response and the magnitude of in vitro IFN-c responses to PPD in a
much larger sample [30]. All 43 infants who did not respond to
TST in this study responded to PPD in vitro. This is consistent with
previous studies in this Gambian population [30], though others
have found good correlation between 6-day IFN-c responses in
vitro and Mantoux induration in healthy Malawian adults [31].
These differences may be explained by differences in the genetic
background of the two populations that were studied or the age of
the study subjects. Adults living in countries such as Malawi have
been exposed chronically to mycobacterial antigens since child-
hood. Chronic antigen exposure probably increases TST and in
vitro IFN-c responses in parallel giving rise to the positive
correlation observed by Black et al [31]. Meanwhile, in an infant
population where NTM exposure is much lower, the dissociation
Table 2. Correlations for individual cytokine responses to various mycobacterial antigens and PHA in BCG vaccinated infants.
IFN-c PHA IFN-c PPD IFN-c Ag85 IFN-c STCF IFN-c KMTB
N
a r
b p value
c N r
b p value N r
b p value N r
b p value N r
b p value
IFN-c PHA - - - 188 0.176 0.0156 171 0.466 1.37610
210 166 0.0629 0.421 188 0.089 0.224
IFN-c PPD -- - 2 0 0 0.540 1.5610
216 207 0.675 7.38610
229 229 0.543 5.79610
219
IFN-c Ag85 -- - 1 8 6 0.503 2.39610
213 200 0.340 8.22610
27
IFN-c STCF -- - 2 0 9 0.615 3.57610
223
IFN-c KMTB -- -
IL-13 PHA IL-13 PPD IL-13 Ag85 IL-13 STCF IL-13 KMTB
N
a r
b p value N
a r
b p value N
a r
b p value N
a r
b p value N
a r
b p value
IL-13 PHA - - - 127 0.381 1.02610
25 47 0.379 0.009 91 0.402 7.66610
25 116 0.1876 0.0582
IL-13 PPD - - - 60 0.101 0.444 107 0.597 1.19610
211 131 0.621 2.41610
215
IL-13 Ag85 -- - 6 00.446 0.3.57610
24 55 20.11 0.425
IL-13 STCF - - - 103 0.417 1.18610
25
IL-13 KMTB -- -
IL-5 PHA IL-5 PPD IL-5 Ag85 IL-5 STCF IL-5 KMTB
N
a r
b p value N
a r
b p value N
a r
b p value N
a r
b p value N
a r
b p value
IL-5 PHA --- 3 5 0.454 0.006 17 20.0627 0.811 28 0.233 0.232 31 0.301 0.0996
IL-5 PPD - - - 36 0.14 0.414 57 0.565 4.59610
26 67 0.635 7.72610
29
IL-5 Ag85 -- - 3 7 0.529 7.54610
24 33 20.0144 0.937
IL-5 STCF -- - 5 3 0.610 1.26610
26
IL-5 KMTB -- -
aNumber of infants for whom both cytokine data were available for correlation analysis.
bSpearman rank-order correlation coefficient.
r values.0.3 with corresponding p values#0.05 are shown in bold.
IFN-c: interferon-gamma; IL-13: interleukin-13; IL-5: interleukin-5; PHA: phytohaemagglutinin; PPD: purified protein derivative; Ag85: antigen 85; STCF: short term culture
filtrate; KMTB: killed Mycobacterium tuberculosis.
doi:10.1371/journal.pone.0003485.t002
Table 3. Correlations between different cytokines responses
to individual mycobacterial antigens.
Antigen cytokine IL-13 IL-5
N
a r
b p value N
a r
b p value
PHA IFN-c 126 0.411 1.76610
26 40 0.022 0.892
IL-13 - - - 28 0.334 0.082
PPD IFN-c 153 0.226 0.005 88 20.150 0.164
IL-13 - - - 60 0.223 0.0865
Ag85 IFN-c 59 0.141 0.286 35 20.368 0.0295
IL-13 -- - 1 2 20.654 0.0211
STCF IFN-c 109 0.285 0.0027 50 20.0893 0.537
IL-13 -- - 3 0 20.129 0.496
KMTB IFN-c 138 0.398 1.33610
26 76 0.071 0.542
IL-13 - - - 45 0.14 0.361
aNumber of infants for whom both cytokine data were available for correlation
analysis.
bSpearman rank-order correlation coefficient.
r values.0.3 with corresponding p values#0.05 are shown in bold.
IFN-c: interferon-gamma; IL-13: interleukin-13; IL-5: interleukin-5; PHA:
phytohaemagglutinin; PPD: purified protein derivative; Ag85: antigen 85; STCF:
short term culture filtrate; KMTB: killed Mycobacterium tuberculosis.
doi:10.1371/journal.pone.0003485.t003
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considered. Rho: Spearman’s rank correlation coefficient; IFN-c: interferon-gamma; IL-13: interleukin-13; IL-5: interleukin-5; PHA: phytohaemagglu-
tinin; PPD: purified protein derivative; Ag85: antigen 85; STCF: short term culture filtrate; KMTB: killed Mycobacterium tuberculosis.
doi:10.1371/journal.pone.0003485.g005
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mechanisms are involved in the two types of response. Both
assays rely on the production of cytokines by antigen specific T
cells but the TST is a delayed hypersensitivity response that
involves injection of antigen into the dermis triggering the
infiltration of specific T lymphocytes into the region in a positive
response. There may be factors that influence this response – e.g.
the local chemokine milieu, that are not relevant to in vitro
responses using blood.
The large number of infants enrolled in this study has revealed
two important findings that have not been described previously in
this age group. Firstly, the new data presented in this paper
Figure 6. A) Histogram showing distribution of BCG scar size in 236 infants measured at 2 months of age following BCG at birth. B) Histogram
showing distribution of average TST size in 202 infants tested at 2 months of age following BCG at birth. C) Scatterplot showing correlation between
interferon-c and TST responses to PPD. D) Box and whisker plot showing median IFN-c concentrations (pg/ml) in supernatant following stimulation
with PPD in infants grouped according the size of TST response. IFN-c: interferon-gamma; PPD: purified protein derivative; TST: tuberculin skin test.
doi:10.1371/journal.pone.0003485.g006
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immune response to BCG in infants, the main recipients of BCG
vaccination. Secondly, we have identified a number of correlations
between responses to different antigens that are worthy of further
discussion and investigation.
A number of factors, both environmental and host-related,
influence immune responses to vaccination. These include the
nutritional status of the vaccinee, exposure to other antigens
through intercurrent infections or administration of other vaccines,
chronic immunosuppressive diseases such as HIV/AIDS, immun-
supressive drug therapy and host genetic factors. Ideally, the design
of a study such as ours should take all these factors into account and
ensure appropriate control measures are included. However, there
are many uncertainties – there will be influences that have yet to be
defined, and for those that are defined we do not know how they
interact with each other to influence the immune responses. For
these reasons, human studies will inevitably have limitations, but we
will focus here on issues of particular relevance to the study of
immune responses to BCG in an infant cohort.
It is well documented that exposure to other mycobacteria
species, including M. tuberculosis, can influence immune responses
to BCG [32]. We believe that M. bovis BCG was the first
mycobacterium the infants in this study were exposed to and the
immune responses we measured were primary responses: we have
previously found that cord blood samples stimulated with
mycobacterial antigens were unresponsive to when evaluated
prior to a related previous study [22]. Furthermore, 2 and 4 month
old Gambian infants who had not received BCG vaccination did
not respond to mycobacterial antigens using similar assays [22,33].
The babies in this study were exclusively breastfed for the first two
months of life and had limited contact with other environmental
sources of non-tuberculous mycobacteria. In terms of exposure to
M. tuberculosis, we excluded infants where there was a family history
of TB or where the mother or any other household member has
symptoms suggestive of TB. The prevalence of TB is also relatively
low in this community, compared to other sub-Saharan African
countries [34]. For these reasons we think it unlikely that the
immune responses we measured were appreciably influenced by
infection with other mycobacteria species.
The HIV prevalence in the antenatal clinic where these infants
were born was very low (,1%) [35], excluding HIV infection as a
major influence on vaccine responses in this population.
Regarding exposure to other antigens such as other EPI vaccines,
the infants did receive polio and hepatitis B vaccines at birth but
all babies received the same dose of the same batch of vaccine
from the same manufacturer, at the same time as they received
BCG. There is much interest currently in the relationship between
helminth infection and response to BCG. Treatment of asymp-
tomatic adult carriers of intestinal helminths led to increased
immunogenicity of BCG compared to untreated controls in
Ethiopia [36], while data from Kenya suggested that in-utero
exposure to Wuchereria bancrofti or Schistosoma haematobium antigens
down-regulated antigen specific IFN-c production after neonatal
BCG vaccination [37]. There are no data on helminth infections
in very young infants on The Gambia but given that all infants in
this study were breastfed and too young to have much soil contact
it is unlikely that many study subjects acquired helminth infection
in the first 2 months of life. Meanwhile, schistosomiasis is rarely
encountered in the coastal region of The Gambia where this study
took place (there are cases to the far East of the country who may
migrate to the coast) and filariasis is not endemic in The Gambia.
Nutritional factors may also have influences responses. Nutri-
tional status as a modifying influence on immune responses is
difficult to assess accurately in this age group as well evaluated
parameters have not been determined. However, we excluded low
birth weight babies (birth weight,2.5 kg) from the study, all babies
were born to healthy mothers, were healthy at birth and had gained
weight appropriately when reviewed at 2 months of age. All babies
were exclusively breastfed during the period of the study. There was
no correlation between birth weight and immune response.
There is a large body of evidence that host genetic factors
influence immune responses both to infectious agents and to
vaccines [38,39,40]. We have shown previously that in vitro IFN-c
responses to PPD in a cohort of infant twins from the same region
as the subjects included in this study are heritable suggesting that
host genetic factors are major determinants of variation in IFN-c
responses [19]. Approximately 40% of the variation in IFN-c
responses to PPD following BCG were attributable to host genetic
factors. Whilst we cannot quantify the relative contribution of each
environmental factor mentioned above, genetic factors are likely to
be the single biggest contributor the the observed variation, in this
study population at least. Further studies are now required to
evaluate the role of genetic factors in other populations.
Although caution is required when extrapolating finding from
one population to others, it is likely that genetic factors will be
important in all populations and what will vary is the relative
contribution of genetic factors to the overall variation and possibly
the specific genes involved. With this caveat, our data suggest that
host genetic factors may be important confounders when IFN-c
responses are used as markers of immunity to new vaccines
undergoing efficacy evaluation in this age group, especially if a
prime-boost strategy is adopted that includes standard BCG. Low
IFN-c responses to mycobacterial antigens following BCG may
not reflect poor immmunogenicity of the vaccine per se, rather that
the host is genetically a low responder. Although IFN-c is an
important marker of immunogenetioity following BCG vaccina-
tion, the potential application of our findings to the clinical testing
of new vaccines for TB will depend on whether there is any
correlation in vivo between the magnitude of the IFN-c response to
vaccination and protection against TB, which is currently not
known. Although there are clear data suggesting that complete
absence of IFN-c responses (as in children in whom the IFN-c
receptor is completed disrupted) leads to severe and disseminated
mycobacterial infection [41,42], there are no data to suggest that
the level of protection directly correlates with level of IFN-c
response. If these parameters do correlate, genetic testing could
identify those at risk of vaccine failure who may benefit from other
measures to prevent the development of TB. Alternatively, host
genotype at key genetic loci may be further parameters to consider
when analysing data from vaccine trials.
Recent developments in genetics such as the Human Genome
Project [43], the Single Nucleotide Polymorphism (SNP) Consor-
tium [44] and the International HapMap project [45,46], coupled
with technological advances, have allowed large scale genotyping to
be undertaken as exemplified by the Wellcome Trust Case Control
Consortium [47]. It is therefore now possible to study the basis of
genetic variation in IFN-c response and to identify DNA variants
that are associated with the magnitude of the response. This in turn
may allow the identification of low responders in advance, in the
same way that pharmacogenetics allows the identification of
individuals at risk of a specific adverse drug reaction [48]. These
findings may also have relevance for IFN-c based diagnostic tests
where the hope is that quantification of level of response may be
helpful to distinguish latent infection from active disease.
The other new findings from this study are the correlations
between the cytokine responses to various mycobacterial antigens and
PHA. The antigens selected included PPD which is a mixed protein
extract derived from M. tuberculosis; M. bovis BCG Ag85 complex, an
Infant Immune Responses to BCG
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subunit vaccine candidate and M. tuberculosis STCF which is rich in
low molecular weight proteins secreted by dividing bacteria.
The correlations observed for cytokine responses to the various
mycobacterial antigens could reflect two mechanisms. Firstly, for
some, e.g. Ag85 and STCF there is overlap in the antigens
stimulating the cytokine response through the same antigen specific
T cell receptors, as Ag 85 is found inSTCF.Thus responsesto Ag85
and STCF were strongly correlated for all three cytokines
investigated. Likewise, responses to PPD and KMTB, which
overlap in terms of the antigens represented, were also strongly
correlated for all three cytokines. Secondly, for antigens that are not
related (e.g. Ag85 and KMTB), it is unlikely that responses are
mediated through shared receptors and we postulate that factors
that influence the cytokine response to these antigens do so in an
antigen independent way. This could involve co-stimulatory
molecules or molecules involved in downstream signalling pathways
shared by all cells irrespective of antigen specificity, once the T cell
receptor has engaged with the different antigens. Activity of such
molecules could vary between individuals (for example through
genetic variation) linking the variation in the responses at the
population level with the observed correlations.
However, the correlations we describe are not complete and
response to one antigen did not predict the response to a different
cytokines with 100% certainty. Thus response to one vaccine will
not necessarily predict response to another.
We did not observe strong correlation between any of the three
cytokines measured for any of the mycobacterial antigens or for PHA
(although weak correlation was observed between IFN-c and IL-13
responses to PHA and KMTB). This is perhaps not surprising as
different subsets of T cell involved in antimycobacterial immunity
produce different cytokines. At the level of a single cell, whilst some
regulatory mechanisms will influence all cytokine functions, there are
also specific factors for individual cytokines. Further studies of
vaccinated infants are required to tease out the relationships between
the different cytokine responses, including the study of single cell
cytokine production in response to mycobacterial antigens.
A further limitation of this study in terms of clinical relevance is
the single timepoint we studied. Further longitudinal follow-updata
would be of key importance to assess whether the observed immune
responses are sustained and whether the variability is sustained or
has an impact on the kinetics of the immune response over time.
In summary, we have studied cytokine responses to neonatal
BCG vaccination in a relatively large cohort comprising 236
infants. We conclude that cytokine responses to mycobacterial
antigens in BCG vaccinated infants are heterogeneous. Of
particular interest are the IFN-c responses since this is an
important marker of protective immunity used for testing new
vaccines for TB. Many variables contribute to the observed
findings. It is likely that host genetic factors underlie the observed
variation in this population [19] and identification of specific
genetic variants involved could lead to more strategic vaccination
programmes and prevention for at risk individuals. However, in
other settings the relative contributions of other non-genetic
factors such as concurrent helminth infection and higher M.
tuberculosis exposure may be higher. Further research is different
populations is required.
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